Welcome to our dedicated page for Immunocore Holdings Plc SEC filings (Ticker: IMCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunocore Holdings plc (IMCR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a Nasdaq‑listed foreign private issuer. Immunocore files current reports on Form 8‑K, annual reports on Form 10‑K and other documents that describe its financial performance, risk factors, capital structure and progress across its ImmTAX platform in oncology, infectious diseases and autoimmune diseases.
Recent Form 8‑K filings dated August 7, 2025 and November 6, 2025 report the release of quarterly financial results and business updates, including net product sales from KIMMTRAK, cash and marketable securities, and status of key clinical trials such as TEBE‑AM, PRISM‑MEL‑301 and ATOM. These filings also incorporate press releases as exhibits, giving additional detail on KIMMTRAK approvals, launches and the company’s pipeline of ImmTAC, ImmTAV and ImmTAAI candidates.
On this page, investors can review Immunocore’s periodic reports to understand how the company accounts for revenue from its commercial product, funds research on TCR bispecifics for HIV and HBV, and advances autoimmune programs like IMC‑S118AI and IMC‑U120AI. Form 4 and related insider transaction filings, when available, can be used to track equity dealings by directors and senior stakeholders.
Stock Titan enhances these IMCR filings with AI‑powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on KIMMTRAK commercialization, clinical trial commitments, liquidity, and material events disclosed under U.S. securities laws, while still allowing access to the full original SEC text for detailed analysis.
T. Rowe Price Investment Management, Inc. filed Amendment No. 3 to a Schedule 13G/A reporting a sizeable passive stake in Immunocore Holdings plc – ADR. As of 12/31/2025, it beneficially owned 5,961,227 ADRs, representing 11.8% of the outstanding class.
The firm reports sole voting and sole dispositive power over all 5,961,227 ADRs, with no shared voting or dispositive power. It certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Immunocore.
Immunocore Holdings plc announced that David Berman has decided to resign as Head of Research & Development, effective February 27, 2026, to pursue another opportunity. The company states that his resignation is not due to any disagreement over operations, policies, or practices.
Immunocore does not plan to appoint a direct replacement for Dr. Berman and instead intends to streamline and leverage its existing R&D structure. This signals a leadership transition within the research organization while maintaining continuity through the current R&D framework.
Immunocore Holdings plc reported a preliminary estimate of its cash, cash equivalents and marketable securities of about $864 million as of December 31, 2025. This figure is based on internal estimates, is unaudited and may change once full year-end financial statements are completed, and any adjustments identified by the company or its independent auditors could be material.
The company also outlined its strategic priorities for 2026 in a press release and updated its corporate presentation with business and strategy updates, including materials to be used at the 44th Annual J.P. Morgan Healthcare Conference. In addition, Immunocore published an updated pipeline chart for KIMMRAK (tebentafusp) and its development-stage therapeutic candidates. These materials are provided as exhibits and, where noted, are furnished rather than filed under securities law.
Immunocore Holdings plc (IMCR) reported insider transactions by its Head of R&D on Form 4. On November 24-25, 2025, the officer exercised employee share options with an exercise price of $17.46 per ordinary share and immediately sold the same number of shares in the market.
The transactions included exercising and selling 100 ordinary shares on November 24 at a sale price of $40.00 per share, and exercising and selling 18,020 ordinary shares on November 25 at a weighted average sale price of $40.03 per share. After these sales, the reporting person held no ordinary shares directly but continued to hold employee share options, including 118,670 options immediately exercisable and expiring on September 12, 2028. All trades were made under a Rule 10b5-1 trading plan adopted on May 9, 2025.
Immunocore Holdings plc furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025, along with recent corporate updates.
The press release is included as Exhibit 99.1 and is incorporated by reference. The materials under Item 2.02 are being furnished, not filed, and therefore are not subject to Section 18 liabilities of the Exchange Act or automatically incorporated into other SEC filings.
Immunocore Holdings plc reported third‑quarter results featuring higher product sales of KIMMTRAK and essentially breakeven earnings. Q3 revenue was $103.7 million, up 29.2% year over year, led by the United States $67.3 million and Europe $33.5 million. Operating loss was $7.2 million, and net loss was $0.2 million (EPS $0.00).
For the nine months, revenue reached $295.5 million, up 30.8%. R&D expense rose to $70.6 million in Q3 on late‑stage trials and pipeline work; SG&A was $39.8 million. The balance sheet showed cash and cash equivalents of $498.4 million and marketable securities of $393.9 million, with convertible notes outstanding at $402.5 million principal. Total shareholders’ equity was $396.6 million.
The company noted an IDMC recommendation to proceed with a 160 mcg dose in the PRISM‑MEL‑301 Phase 3 brenetafusp trial. Shares outstanding were 50,530,419 as of October 31, 2025.
This Schedule 13G/A reports that Eli Lilly & Co. and Eli Lilly S.A. filed an amendment concerning their holdings in Immunocore Holdings plc ordinary shares (CUSIP 54258D105) related to the reporting event dated 09/30/2025. Both reporting entities state they beneficially own 0 ordinary shares, representing 0.0% of the class, with 0 shares of sole or shared voting or dispositive power. The filing lists issuer headquarters at 90 Park Drive, Milton Park, Abingdon, Oxfordshire, UK. Signatures show the amendment was executed by Christopher Anderson as Attorney-in-Fact for both filers on 10/03/2025, and reference previously filed powers of attorney incorporated by reference.
David M. Berman, Head of R&D and a director at Immunocore Holdings plc (IMCR), reported transactions on 09/30/2025 showing net disposal of his ordinary shares. He acquired 61,849 shares by exercising employee options at an exercise price of $17.46 and, under the same date, sold 61,849 ordinary shares at a weighted average price of $35.23, with individual sale prices ranging from $35.01 to $35.48.
The exercise was immediately exercisable and the sales were executed pursuant to a Rule 10b5-1 trading plan adopted on May 9, 2025. After these transactions, the reporting person holds 0 ordinary shares directly and reports 136,790 shares underlying options/options-related rights in total.